share_log

Wells Fargo Maintains Overweight on Sangamo Therapeutics, Lowers Price Target to $4

Wells Fargo Maintains Overweight on Sangamo Therapeutics, Lowers Price Target to $4

富国银行维持对Sangamo Therapeutics的增持,将目标股价下调至4美元
Benzinga ·  2023/08/10 10:08

Wells Fargo analyst Yanan Zhu maintains Sangamo Therapeutics (NASDAQ:SGMO) with a Overweight and lowers the price target from $5 to $4.

富国银行分析师朱亚南维持Sangamo Therapeutics(纳斯达克股票代码:SGMO)的增持,并将目标股价从5美元下调至4美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发